Targets › MTAP
10 programs from 8 companies in 25 trials: 20 Phase 1, 5 Phase 2; Oncology, Other; next expected readout Nov 2026.
Catalyzes the phosphorolytic cleavage of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose1-phosphate. Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis. (UniProt, Q13126)
Open in Phaseline: the race on MTAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Navlimetostat (BMS-986504) Selective, MTA-cooperative PRMT5 inhibitor | PRMT5, MTAP | Phase 2 | Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants … | Nov 2026 |
| Bristol-Myers Squibb | BMS-986504 (MRTX1719) Selective MTA-cooperative inhibitor of PRMT5 | MTAP, PRMT5 | Phase 2 | Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion … | Jan 2027 |
| BeOne Medicines | BGB-58067 MTAP inhibitor | MTAP | Phase 1 | Healthy Volunteers; Advanced Solid Tumor | Jul 2027 |
| Suzhou Genhouse Bio Co., Ltd. | GH56 Capsule MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumors With MTAP Deletion | Dec 2027 |
| Heronova Pharmaceuticals | DC50292A MTAP inhibitor | MTAP | Phase 1 | Solid Tumor Malignancies | Jan 2028 |
| Haisco Pharmaceutical Group | HSK41959 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumors | May 2028 |
| Gilead Sciences | GS-5319 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumor | May 2028 |
| Abbisko Therapeutics | ABSK131 MTAP inhibitor | MTAP | Phase 1 | Solid Tumors (Phase 1) | Dec 2028 |
| CytosinLab Therapeutics | CTS3497 MTAP inhibitor | MTAP | Phase 1 | Solid Tumor | Dec 2028 |
| Gilead Sciences | GS-2426 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumors | Jan 2029 |
Advanced Solid Tumors (3) Healthy Volunteers (2) Advanced Solid Tumor (2) Solid Tumors (1) Pancreatic Ductal Adenocarcinoma (1) Healthy Participants (1) Healthy Female Participants (1) Healthy Female Adults (1) Phase 2 Study (1) Non-Small Cell Lung Cancer (1) Advanced Cancer (1) Solid Tumor Malignancies (1)
small molecule (9), mixed (1)
Bristol-Myers Squibb (2) Gilead Sciences (2) BeOne Medicines (1) Heronova Pharmaceuticals (1) Suzhou Genhouse Bio Co., Ltd. (1) CytosinLab Therapeutics (1) Haisco Pharmaceutical Group (1) Abbisko Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.